Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790 is registered in ClinicalTrials.gov with Cognition Therapeutics as lead sponsor.

NCT NCT03507790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03507790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Lead sponsor
Cognition Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2018
Completion date
May 29, 2024
Enrollment
153 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate alzheimer's disease